Kalocyte provides red blood cell substitutes used for trauma care related services.
Kalocyte has raised $5K in total funding. The most recent round was Grant. The last funding was announced in August 2023.
Kalocyte's investors include NYBC Ventures, BioGenerator, University System of Maryland Momentum Fund, Small Business Innovation Research, Comcast RISE.
Kalocyte is headquartered in Baltimore, United States.
Kalocyte provides red blood cell substitutes used for trauma care related services.
Kalocyte is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kalocyte — Funding & Investors." VCBacked, August 23, 2023, https://www.vcbacked.co/company/kalocyte. Accessed September 29, 2026.
VCBacked. (2023). Kalocyte — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/kalocyte
{{cite web |title=Kalocyte — Funding & Investors |url=https://www.vcbacked.co/company/kalocyte |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated